Compare NWTG & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NWTG | CDIO |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.4M |
| IPO Year | 2022 | 2021 |
| Metric | NWTG | CDIO |
|---|---|---|
| Price | $1.28 | $2.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.4K | ★ 29.7K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.09 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,135,000.00 | $14,825.00 |
| Revenue This Year | $53.21 | $171,906.75 |
| Revenue Next Year | $40.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 136.14 | N/A |
| 52 Week Low | $0.70 | $0.97 |
| 52 Week High | $2.07 | $7.91 |
| Indicator | NWTG | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 63.99 | 61.91 |
| Support Level | $0.99 | $1.68 |
| Resistance Level | $1.39 | $2.16 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 80.00 | 68.33 |
Newton Golf Co Inc is a technology-forward golf company engaged in designing, manufacturing, and selling performance golf equipment, including premium golf shafts and putters, and focuses on developing technology-driven golf products intended to enhance player performance. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.